Lemborexant
From Infogalactic: the planetary knowledge core
175px | |
Systematic (IUPAC) name | |
---|---|
(1R,2S)-2-[(2,4-dimethylpyrimidin-5-yl)oxymethyl]-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropane-1-carboxamide
|
|
Clinical data | |
Legal status |
|
Identifiers | |
CAS Number | 1369764-02-2 |
ATC code | None |
PubChem | CID: 56944144 |
ChemSpider | 34500836 |
Chemical data | |
Formula | C22H20F2N4O2 |
Molecular mass | 410.417 g/mol |
|
|
|
Lemborexant (INN) (code name E-2006) is a dual antagonist of the orexin OX1 and OX2 receptors which is under development by Eisai for the treatment of insomnia.[1] [2][3] As of December 2014, it is in phase II clinical trials.[4]
See also
References
<templatestyles src="Reflist/styles.css" />
Cite error: Invalid <references>
tag; parameter "group" is allowed only.
<references />
, or <references group="..." />
External links
<templatestyles src="Asbox/styles.css"></templatestyles>
Categories:
- Pages with reference errors
- Pages with broken file links
- Chemical articles having calculated molecular weight overwritten
- Infobox drug articles without a structure image
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without UNII source
- Drugs not assigned an ATC code
- Articles containing unverified chemical infoboxes
- Carboxamides
- Hypnotics
- Orexin antagonists
- Organofluorides
- Pyrimidines
- Pyridines
- Nervous system drug stubs